Versant Ventures has launched Granite Bio with $100 million in funding, advancing two novel antibody drugs targeting inflammatory conditions through its Ridgeline Therapeutics initiative.
iOnctura has dosed the first patient in its randomized Phase II OCULE-01 study evaluating roginolisib, an allosteric PI3Kδ modulator, in patients with metastatic uveal melanoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.